当前位置: X-MOL 学术Nat. Genet. › 论文详情
ARID1A determines luminal identity and therapeutic response in estrogen-receptor-positive breast cancer
Nature Genetics ( IF 25.455 ) Pub Date : 2020-01-13 , DOI: 10.1038/s41588-019-0554-0
Guotai Xu; Sagar Chhangawala; Emiliano Cocco; Pedram Razavi; Yanyan Cai; Jordan E Otto; Lorenzo Ferrando; Pier Selenica; Erik Ladewig; Carmen Chan; Arnaud Da Cruz Paula; Matthew Witkin; Yuanming Cheng; Jane Park; Cristian Serna-Tamayo; HuiYong Zhao; Fan Wu; Mirna Sallaku; Xuan Qu; Alison Zhao; Clayton K Collings; Andrew R. D’Avino; Komal Jhaveri; Richard Koche; Ross L. Levine; Jorge S. Reis-Filho; Cigall Kadoch; Maurizio Scaltriti; Christina S. Leslie; José Baselga; Eneda Toska

Mutations in ARID1A, a subunit of the SWI/SNF chromatin remodeling complex, are the most common alterations of the SWI/SNF complex in estrogen-receptor-positive (ER+) breast cancer. We identify that ARID1A inactivating mutations are present at a high frequency in advanced endocrine-resistant ER+ breast cancer. An epigenome CRISPR–CAS9 knockout (KO) screen identifies ARID1A as the top candidate whose loss determines resistance to the ER degrader fulvestrant. ARID1A inactivation in cells and in patients leads to resistance to ER degraders by facilitating a switch from ER-dependent luminal cells to ER-independent basal-like cells. Cellular plasticity is mediated by loss of ARID1A-dependent SWI/SNF complex targeting to genomic sites of the luminal lineage-determining transcription factors including ER, forkhead box protein A1 (FOXA1) and GATA-binding factor 3 (GATA3). ARID1A also regulates genome-wide ER–FOXA1 chromatin interactions and ER-dependent transcription. Altogether, we uncover a critical role for ARID1A in maintaining luminal cell identity and endocrine therapeutic response in ER+ breast cancer.
更新日期:2020-01-14

 

全部期刊列表>>
2020新春特辑
限时免费阅读临床医学内容
ACS材料视界
科学报告最新纳米科学与技术研究
清华大学化学系段昊泓
自然科研论文编辑服务
加州大学洛杉矶分校
上海纽约大学William Glover
南开大学化学院周其林
课题组网站
X-MOL
北京大学分子工程苏南研究院
华东师范大学分子机器及功能材料
中山大学化学工程与技术学院
试剂库存
天合科研
down
wechat
bug